JOINT TRAUMA SYSTEM CLINICAL PRACTICE GUIDELINE (JTS CPG)

Blunt Abdominal Trauma, Splenectomy, and Post-Splenectomy Vaccination (CPG ID: 09)
To provide guidance on the management of combat casualties who sustain blunt abdominal trauma.

Contributors
CAPT Zsolt Stockinger, MC, USN
CDR Daniel Grabo, MC, USN
MAJ AVI Benov, MC, IDF
Homer Tien, MC, CAF
LTC Jason Seery, MC, USA
CDR Ashley Humphries, MC, USN

First Publication Date: 01 Jul 2006
Publication Date: 12 Aug 2016
Supersedes CPG dated 27 Sep 2012

TABLE OF CONTENTS

Background ......................................................................................................................................................... 2
OPSI Prevention .................................................................................................................................................. 3
Vaccine Candidates ............................................................................................................................................. 3
Vaccine Dosing ................................................................................................................................................... 3
Vaccination Administration Time ....................................................................................................................... 3
Vaccination Documentation ................................................................................................................................. 4
Performance Improvement (PI) Monitoring ........................................................................................................... 4
  Intent (Expected Outcomes) ............................................................................................................................. 4
  Performance/Adherence Measures .................................................................................................................... 4
  Data Source ....................................................................................................................................................... 5
System Reporting & Frequency ............................................................................................................................ 5
Responsibilities .................................................................................................................................................... 5
References ............................................................................................................................................................ 5
Appendix A: Algorithm for Evaluating Blunt Abdominal Trauma ................................................................. 6
Appendix B: Timing of Vaccination after Splenectomy .................................................................................... 7
Appendix C: Additional Information Regarding Off-Label Uses in CPGs .................................................... 9
BACKGROUND

Unlike penetrating abdominal injuries where the decision to operate is relatively straightforward, those combat casualties that sustain Blunt Abdominal Trauma (BAT) offer more of a diagnostic and clinical challenge. With the improvements in body armor, truncal injury has decreased despite increasingly more lethal weapon systems. With the advent of Improvised Explosive Devices (IEDs), however, more casualties are presenting with evidence of BAT. While Computed Tomography (CT) scans are available to assist the provider in decision making at a Role 3 facility, providers at far forward surgical units must decide to operate based on a physical and focused assessment with sonography for trauma (FAST) exam.¹

It is incumbent on the senior surgeon at each facility to ensure the staff understands their resource limitations and the inherent limitations associated with the use of the FAST exam to diagnose a hemoperitoneum. For hemodynamically unstable trauma patients with a positive FAST, exploratory laparotomy should be undertaken immediately. Rarely, patients with a positive FAST and/or CT scan may be managed non-operatively if they are already at a Role 3 facility that can ensure adequate clinical follow-up and evaluation. Patients who have a positive FAST exam and/or evidence of hemoperitoneum through CT at a surgical facility should not be transferred until any and all ongoing intraabdominal hemorrhage is completely assessed and controlled. The benefits of non-operative management do not outweigh the risks of an in-flight hemorrhagic emergency with no potential for therapeutic surgical intervention. Patients who evolve peritonitis by physical exam or continue to consume blood products in order to maintain blood pressure warrant exploratory laparotomy. An algorithmic approach to the blunt trauma patient is presented in Appendix A.

Splenic injury grading is presented in Table 1 below. All grade IV-V splenic injuries should undergo splenectomy due to the high risk of failure of non-operative management with or without splenic embolization² and the need for prolonged transportation out of theater. Lacerated spleens of any grade with active hemorrhage encountered during laparotomy for any reason are best managed by splenectomy. If the tactical situation permits stable grade III splenic injuries without active extravasation, pseudoaneurysm, hemoperitoneum on CT scan or other indications for laparotomy that may include, but are not limited to associated injury may undergo attempt of non-operative management under the direct supervision of an experienced trauma surgeon.³ Ideally, patients undergoing attempted splenic salvage should be monitored in the Role 3 facility for at least 48 hours prior to strategic evacuation out of theater. In Role 3 facilities with interventional radiology capabilities, embolization of grade III splenic injuries may be considered as an adjunct to non-operative management. Embolization is not definitive treatment for splenic injuries so these patients must also be monitored for 48 hours following the procedure and prior to strategic aeromedical evacuation from theater.

Table 1. Organ Injury Scaling: Spleen

<table>
<thead>
<tr>
<th>Grade</th>
<th>Injury Description</th>
<th>AIS 90</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Subcapsular Haematoma, &lt;10% surface area</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>Laceration Capsular tear, &lt;1cm parenchymal depth</td>
<td>2</td>
</tr>
<tr>
<td>II</td>
<td>Subcapsular Haematoma, 10-50% surface area</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>Intraparenchymal, &lt;5cm diameter</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>Laceration 1-3cm parenchymal depth not involving a parenchymal vessel</td>
<td>2</td>
</tr>
<tr>
<td>III</td>
<td>Subcapsular Haematoma, &gt;50% surface area or expanding.</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>Ruptured subcapsular or parenchymal haematoma</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>Intraparenchymal haematoma &gt;5cm</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>Laceration &gt;3cm parenchymal depth or involving trabecular vessels</td>
<td>3</td>
</tr>
<tr>
<td>IV</td>
<td>Laceration of segmental or hilar vessels producing major devascularization (&gt;25% of spleen)</td>
<td>4</td>
</tr>
<tr>
<td>IV</td>
<td>Laceration Completely shattered spleen</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>Vascular Hilar Vascular Injury which devascularized spleen</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>Advance one grade for multiple injuries to same organ up to Grade III.</td>
<td></td>
</tr>
</tbody>
</table>

1. Guideline Only/Not a Substitute for Clinical Judgment
A contrast CT scan should be obtained at 48 hours (and before aeromedical evacuation out of the Role 3) to assess for complications such as pseudoneuromys formation on all patients undergoing non-operative management of splenic injury. Indicators of failure of non-operative management of the spleen include but are not limited to any need for blood transfusion and any hypotensive episode. For Grade I-III splenic injuries success rate of non-operative management with embolization reach 99-100%. Patients who fail non-operative management of the spleen require splenectomy at the Role 3 prior to aeromedical evacuation. It must be stressed that placing a patient in the aeromedical environment is akin to discharge from the facility WITHOUT ACTIVITY RESTRICTION and without the option of re-admission during the complete inter-facility transport between theaters which must be assumed to be a minimum of 12 hours. Additionally, the patient’s history should be discussed between the referring and accepting surgeons prior to evacuation. Patients with Grade III splenic injury and Traumatic Brain Injury (TBI) should undergo splenectomy due to the fact that hypotension with TBI will double mortality. Angiography and embolization for blunt injuries of other visceral organs may be used as an adjunctive procedure and should be determined on a case by case basis.

**OPSI PREVENTION**

OPSI is a rare but devastating complication with a case mortality rate in most studies approaching 50%. OPSI represents a life-long risk, with the incidence in trauma patients estimated to be <0.5%; it is estimated that splenectomized individuals are up to 540 time more susceptible to lethal sepsis than the general population. Patients present with nonspecific flu-like symptoms rapidly progressing to fulminant sepsis, consumptive coagulopathy, bacteremia, and untimely death within 12-48 hours. The infections are typically caused by encapsulated organisms including Streptococcus pneumonia, H. Influenza type B, and Neisseria meningitis. One study demonstrated that only 56.7% of patients receive all vaccines needed. Since these patients are at risk for OPSI, there must be a standardized process to provide post-splenectomy vaccination, accurate documentation, and life-long tracking to identify outcomes.

**VACCINE CANDIDATES**

All splenectomized patients and those deemed to be functionally asplenic (e.g., <51% normal architecture and/or vascularization in the remaining splenic segment).

**VACCINE DOSING**

  - One-time revaccination after 5 years is recommended for persons aged 19 through 64 years with functional or anatomic asplenia (splenectomy).
  - Approved abbreviation: HiB
  - For patients not vaccinated in infancy or on accession to military service:
- Meningococcal (Menactra® or Menveo®): Single Dose.
  - Approved abbreviation: MCV4.
  - One-time revaccination after 5 years is recommended for persons aged 19 through 64 years with functional or anatomic asplenia (splenectomy).
Blunt Abdominal Trauma, Splenectomy, and Post-Splenectomy Vaccination

CPG ID: 09

Guideline Only/Not a Substitute for Clinical Judgment

VACCINATION ADMINISTRATION TIME

All patients for Aeromedical Evacuation: Administer all three vaccines in the immediate postoperative period at the first facility that can do so. Role 3 and Role 4 facilities should not assume that vaccination have occurred prior to arrival.

Host nation and other patients NOT evacuated out of theater: Administer all three vaccines in the immediate postoperative period at the first available opportunity, but no later than the 14th postoperative day.

VACCINATION DOCUMENTATION

A dated, timed, and signed physician order for all three vaccines will be documented on the physician order form. If any or all three vaccines are not ordered, there must be clear documentation indicating the rationale for why one/more vaccines were not ordered. Doing so will facilitate clear communication along the continuum of care.

Vaccine administration documentation on the medication administration record (MAR) will include date, time, dose, lot number/lot sticker, manufacturer, and nurse signature for each of the three vaccines. If any or all of the three vaccines are ordered, but not administered (for any reason), the ordering physician must be notified, and there must be clear documentation indicating this and the rationale for why one/more vaccines were not administered. Also, document which provider was notified. This facilitates clear communication along the continuum of care.

Documentation in the electronic medical record for the physician order, dispensing from the pharmacy or immunization clinic, and nursing administration is preferred when possible. Documentation of vaccination is highly recommended in the service specific vaccination tracking systems (MEDPROS for Army, MRRS for Navy/Marine/Coast Guard, and ASIMS for Air Force) if available at the treating facility or operating base.

PERFORMANCE IMPROVEMENT (PI) MONITORING

INTENT (EXPECTED OUTCOMES)

- All patients with Splenic lacerations grade IV-V will have splenectomy prior to theater evacuation
- All patients with blunt abdominal trauma who remain unstable after initial resuscitation will undergo exploratory.
- To ensure all patients in the CENTCOM AOR who are rendered asplenic by trauma and/or surgery are completely vaccinated against OPSS.

PERFORMANCE/ADHERENCE MEASURES

- All patients with grade IV-V Splenic lacerations underwent splenectomy prior to transport out of theater.
- All blunt abdominal trauma patients who remained unstable after initial resuscitation underwent exploratory laparotomy.
- All patients undergoing splenectomy and those who are functionally asplenic received all three post-splenectomy vaccines.
- All post-splenectomy vaccinations are documented in the physician orders and nursing MARs.

All vaccination documentation is complete and accurate to include date, time, dose, lot number/lot sticker, manufacturer, and nurse signature for each of the three vaccines administered.
DATA SOURCE

- Patient Record
- DoD Trauma Registry (DoDTR)
- Nursing MAR

SYSTEM REPORTING & FREQUENCY

The above constitutes the minimum criteria for PI monitoring of this CPG. System reporting will be performed annually; additional PI monitoring and system reporting may be performed as needed. The system review and data analysis will be performed by the Joint Trauma System (JTS) Director, JTS Program Manager, and the Joint JTS Performance Improvement Branch.

RESPONSIBILITIES

It is the trauma team leader’s responsibility to ensure familiarity, appropriate compliance and PI monitoring at the local level with this CPG.

REFERENCES


10. Recommended Adult Immunization Schedule: UNITED STATES 2011, the Centers for Disease Control (CDC) and Prevention’s Advisory Committee on Immunization Practices (ACIP); www.cdc.gov/vaccines.
APPENDIX A: ALGORITHM FOR EVALUATING BLUNT ABDOMINAL TRAUMA

Guidelines apply for Level II+ and Level III with surgical capability. FAST exam reliability is very operator dependent. Providers who rely on FAST exam must be mindful of risk of false negative exam. Only providers with personal experience of accurate findings should rely on the FAST exam as a screening tool for hemoperitoneum. If splenic preservation is to be attempted (including embolization), the patient should remain in the facility for a minimum of 48 hours of observation before being transported to another facility.

FAST: Focused assessment with sonography for trauma
APPENDIX B: TIMING OF VACCINATION AFTER SPLENECTOMY

By COL Greg Beilman, Director, Joint Theater Trauma System, 22 Dec 2008.

OPSS is an uncommon but rapidly life-threatening complication of splenectomy, which occurs at the rate of approximately 1 per 1000 patient-years. Immunization with vaccines protective against encapsulated organisms (e.g. Streptococcus pneumonia, Nisseria meningitis, Hemophilus influenzae) drops this risk to approximately 1 per 106 patient-years. Appropriate prophylactic immunization of injured warriors undergoing splenectomy was not reliably occurring until the recent development of a COG suggesting immunization with appropriate vaccines immediately after splenectomy. During the most recent 2 months of evaluation, immunization rates are 100%. At issue is the effectiveness of vaccination at this time period. A literature search was performed with recent pertinent references listed below.

A summary of the pertinent studies is included in Table 1 below. The Surgical Infection Society recommends that patients who cannot be immunized prior to splenectomy receive vaccination 2 weeks after splenectomy (Grade D recommendation: expert opinion). In summary, antibody responses to vaccination in humans after splenectomy have been shown to improve if there is a two week delay in immunization. Likely due to the very low incidence of overwhelming post-splenectomy sepsis, there is no evidence to support an outcome benefit related to this delay.

Table 1. Summary of Pertinent Studies

<table>
<thead>
<tr>
<th>Reference</th>
<th>Species</th>
<th>Endpoint</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shatz</td>
<td>Human (splenectomy)</td>
<td>Antibody response</td>
<td>Improved Ab response at 2 weeks (= normal controls) after splenectomy compared to 1 day, 1 week.</td>
</tr>
<tr>
<td>Werner</td>
<td>Rat (splenectomy)</td>
<td>Antibody response</td>
<td>Improved response 1 week, 1 month post-splenectomy</td>
</tr>
<tr>
<td>Schreiber</td>
<td>Rat (splenectomy, S pneumo challenge)</td>
<td>Survival</td>
<td>No difference in survival in early (1 day) vs. late (42 d) immunization. Both better than unimmunized controls.</td>
</tr>
<tr>
<td>Clayer</td>
<td>Rat (splenectomy)</td>
<td>Antibody response</td>
<td>Ab response decreased early (1 day) and late (1 year) after splenectomy compared to normal controls.</td>
</tr>
<tr>
<td>Werner</td>
<td>Rat (Hem shock, then splenectomy)</td>
<td>Antibody response</td>
<td>No difference in Ab response 1 d vs 28 d s/p splenectomy plus shock.</td>
</tr>
</tbody>
</table>

Currently there is little evidence that patients requiring immunization are not receiving them. Of patients receiving splenectomy as part of their treatment in theater between Jan and Dec of 2011, 30/31 received appropriate immunization (Figure 2 and Figure 1 below). While it appears that antibody response to immunization is improved in humans when waiting two weeks post-injury, there is no evidence to suggest that this delay is protective for overwhelming post-splenectomy sepsis. The current process of immunization at the time of splenectomy is yielding appropriate immunizations in warfighters requiring splenectomy and will be continued.
Blunt Abdominal Trauma, Splenectomy, and Post-Splenectomy Vaccination

Figure 1. Post Splenectomy Patients Receiving Vaccines: 2001-2010.

<table>
<thead>
<tr>
<th>Year</th>
<th>Splenectomies</th>
<th>Pt Receiving Vaccines</th>
</tr>
</thead>
<tbody>
<tr>
<td>2003</td>
<td>6</td>
<td>0</td>
</tr>
<tr>
<td>2004</td>
<td>18</td>
<td>0</td>
</tr>
<tr>
<td>2005</td>
<td>35</td>
<td>1</td>
</tr>
<tr>
<td>2006</td>
<td>49</td>
<td>5</td>
</tr>
<tr>
<td>2007</td>
<td>38</td>
<td>3</td>
</tr>
<tr>
<td>2008</td>
<td>14</td>
<td>8</td>
</tr>
<tr>
<td>2009</td>
<td>19</td>
<td>16</td>
</tr>
<tr>
<td>2010</td>
<td>27</td>
<td>25</td>
</tr>
</tbody>
</table>

Figure 2. Post Splenectomy Patients Receiving Vaccines 2011

<table>
<thead>
<tr>
<th>Month</th>
<th>Patients Receiving Splenectomies</th>
<th>Patients Receiving Vaccines</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jan-11</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Feb-11</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Mar-11</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Apr-11</td>
<td>7</td>
<td>4</td>
</tr>
<tr>
<td>May-11</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td>Jun-11</td>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td>Jul-11</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Aug-11</td>
<td>5</td>
<td>3</td>
</tr>
<tr>
<td>Sep-11</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Oct-11</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Nov-11</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Dec-11</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>
APPENDIX C: ADDITIONAL INFORMATION REGARDING OFF-LABEL USES IN CPGS

PURPOSE

The purpose of this Appendix is to ensure an understanding of DoD policy and practice regarding inclusion in CPGs of “off-label” uses of U.S. Food and Drug Administration (FDA)–approved products. This applies to off-label uses with patients who are armed forces members.

BACKGROUND

Unapproved (i.e. “off-label”) uses of FDA-approved products are extremely common in American medicine and are usually not subject to any special regulations. However, under Federal law, in some circumstances, unapproved uses of approved drugs are subject to FDA regulations governing “investigational new drugs.” These circumstances include such uses as part of clinical trials, and in the military context, command required, unapproved uses. Some command requested unapproved uses may also be subject to special regulations.

ADDITIONAL INFORMATION REGARDING OFF-LABEL USES IN CPGS

The inclusion in CPGs of off-label uses is not a clinical trial, nor is it a command request or requirement. Further, it does not imply that the Military Health System requires that use by DoD health care practitioners or considers it to be the “standard of care.” Rather, the inclusion in CPGs of off-label uses is to inform the clinical judgment of the responsible health care practitioner by providing information regarding potential risks and benefits of treatment alternatives. The decision is for the clinical judgment of the responsible health care practitioner within the practitioner-patient relationship.

ADDITIONAL PROCEDURES

Balanced Discussion

Consistent with this purpose, CPG discussions of off-label uses specifically state that they are uses not approved by the FDA. Further, such discussions are balanced in the presentation of appropriate clinical study data, including any such data that suggest caution in the use of the product and specifically including any FDA-issued warnings.

Quality Assurance Monitoring

With respect to such off-label uses, DoD procedure is to maintain a regular system of quality assurance monitoring of outcomes and known potential adverse events. For this reason, the importance of accurate clinical records is underscored.

Information to Patients

Good clinical practice includes the provision of appropriate information to patients. Each CPG discussing an unusual off-label use will address the issue of information to patients. When practicable, consideration will be given to including in an appendix an appropriate information sheet for distribution to patients, whether before or after use of the product. Information to patients should address in plain language: a) that the use is not approved by the FDA; b) the reasons why a DoD health care practitioner would decide to use the product for this purpose; and c) the potential risks associated with such use.